AUM Biosciences, a biotechnology company, to go public via a SPAC merger with Mountain Crest Acquisition V, a publicly traded special purpose acquisition company, in a $400m deal. “AUM is a unique and compelling investment opportunity, with its clinical-stage diversified pipeline of precision therapeutic candidates and global strategic partnerships with industry heavyweights, pointing to significant future growth potential and allowing the company to have a greater US footprint. I am thrilled to be partnering with Mr. Doshi and his exceptional team to bring their vision to fruition,” Suying Liu, Mountain Crest Chairman, CEO and CFO.